First-in-human Study of IO-108 as Single Agent and in Combination With a PD-1 Immune Check Point Inhibitor in Patients With Advanced Solid Tumors

NYU Langone Health (131), New York

UPMC Hillman Cancer Center (105), Pittsburgh

Maryland Oncology Hematology, PA (145) (USOR SITE), Columbia

NEXT Oncology-Virginia (121), Fairfax

Carolina BioOncology (102), Huntsville

University of Florida (125), Gainesville

Florida Cancer Specialists (134), Lake Mary

Memorial Cancer Institute (146), Pembroke Pines

Florida Cancer Specialists & Research Institute (103), Sarasota

Hematology Oncology (136), Stuart

Gabrail Cancer Center (128), Canton

Oncology Hematology Care Clinical Trials, LLC (144) (USOR SITE), Cincinnati

Indiana University Melvin and Bren Simon Comprehensive Cancer Center (123), Indianapolis

Karmanos Cancer Institute (126), Detroit

St. Vincent - Frontier Cancer Center (135), Billings

Texas Oncology - Baylor Charles A. (143) (USOR SITE), Dallas

MD Anderson Cancer Center (101), Houston

Oncology Consultants, P.A. (138), Houston

Texas Oncology - Austin (142) (USOR SITE), Austin

Rocky Mountain Cancer Centers, LLP (141) (USOR SITE), Lone Tree

Arizona Oncology Associates, PC-HOPE (140) (USOR SITE), Tucson

Beverly HIlls Cancer Center (129), Beverly Hills

Providence Cancer Institute (104), Portland

Swedish Cancer Institute (147), Seattle